Close Menu

Sysmex

Sysmex anticipates delivering the kit to Japanese medical institutions this month for diagnosis of the SARS-CoV-2 infection.

The company believes cytogeneticists will adopt its panel to get high-quality SNV and CNV data in a single assay.

The reagent is used for the detection of cytokeratin 19 mRNA in surgically removed sentinel lymph nodes in order to diagnose lymph node metastasis.

The test, which will be developed using the companies' respective technologies, will be marketed by Biolidics following clinical validation.

The two companies have  been working together since February and now are formalizing plans to develop and test new products.

Biocartis' Idylla called some colorectal cancer samples negative that Sysmex Inostics's OncoBEAM called positive, but the clinical implications may be complex.

The firm believes that physicians can use information from the cell-free DNA analyzed by the assay to determine whether to use anti-EGFR drugs during treatment.

The firms said they will integrate their capabilities and competencies to offer solutions to global pharmaceutical customers.

The alliance follows a marketing deal signed with Sysmex Europe that covers Europe, the Middle East, and Africa.

Pages

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.